“Selective JAK1 Inhibition Using Upadacitinib for the Management of Inflammatory Bowel Diseases: The Powerful Pill” (2023) Canadian IBD Today, 1(S11), pp. 2–11. doi:10.58931/cibdt.2023.1S1121.